Hyderabad-based company Bharat Biotech has handed over the data of Phase-3 clinical trial of Covaxin to the government.
News agency ANA quoted sources as saying that the data of clinical trials conducted in the third phase of Covaxin has been submitted to the Drug Controller General of India (DCGI).
In April this year, Bharat Biotech had said that according to Phase III results, Covaxin has shown 78 per cent efficacy against mild, moderate and severe cases of corona.
Bharat Biotech has submitted data for the Phase III clinical trial of Covaxin to the Drugs Controller General of India (DCGI), government sources said on Tuesday.
In fact, the Hyderabad-based vaccine manufacturer has come under sharp criticism for the delay in releasing the Phase III clinical trial of Covaxin.
DCGI approved Covaxin for emergency use in India in January based on its Phase 1 and 2 trials.
Recently, an early study claimed that the Covishield vaccine produces more antibodies against coronavirus infection than Covaxin.
The study showed that after two shots of the vaccines, 98 percent of CoviShield recipients showed an antibody response, compared to 80 percent of Covaxin recipients.
Bharat Biotech, however, downplayed the study, saying that the preliminary research had several flaws.
The firm also stated that the study was not reviewed and was not scientifically designed.
News Source: HindustanTimes
